CD274 and non-small cell lung carcinoma: A recent phase 3 randomized trial (IMpower 010) showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stages II–IIIA NSCLC; the benefit was more pronounced in the subgroup with PDL1 TPS ≥1% (61).